Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marriott International Inc (MAR) vs Merck & Co., Inc. (MRK) Price & Performance

Marriott International Inc Trade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Marriott International Inc vs Merck & Co., Inc. — how do they compare? Marriott International Inc trades at $349.48 (market cap $90.86B), while Merck & Co., Inc. trades at $130.29 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 3.6× Marriott International Inc 's market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.

MARMRK
Market Cap
$90.86B$323.00B
Sector
Consumer CyclicalHealth
52-Week High
$402.54$131.84
52-Week Low
$259.04$77.60
Enterprise Value
$108.17B$369.77B
Dividend Yield
0.84%2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marriott International Inc

Marriott International (MAR) trades at $353.91, down 1.6% in the last 24 hours, with a bearish technical signal. The stock shows strong profitability with a net income margin of 9.62% and ROE of 1,446.77%, but faces high valuation ratios like a P/E of 36.64. Recent Q2 2026 earnings beat estimates at $3.19 per share, and the company raised its 2026 outlook, though revenue missed expectations. A quarterly dividend of $0.73 per share was declared, payable on June 30, 2026.

The outlook is mixed: robust fee growth and a record pipeline support upside, but elevated debt and premium valuation pose risks. Analysts are generally positive with a consensus price target of $387.31, though near-term volatility may persist due to macroeconomic headwinds and regional weaknesses in the Middle East.

Merck & Co., Inc.

MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.

Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Marriott International Inc

Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.

Read more on MAR

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK